📇 Rhumatologue · ST HERBLAIN · (44) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
14 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
129.9 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHU DE NANTES SITE LAENNEC
BD JACQUES MONOD, 44800 ST HERBLAIN
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Respiration; international review of thoracic diseases · 2020
<b><i>Background:</i></b> Therapeutic bronchoscopy (TB) is an accepted strategy for the symptomatic management of central airway malignant obstruction. Stent insertion is recommended in case of extrinsic compression, but its value in preventing airway re-obstruction after endobronchial treatment without extrinsic compression is unknown. <b><i>Objective:</i></b> Silicone stent Placement in symptomatic airway Obstruction due to non-small cell lung Cancer (SPOC) is the first randomized controlled trial investigating the potential benefit of silicone stent insertion after successful TB in symptomatic malignant airway obstruction without extrinsic compression. <b><i>Method:</i></b> We planned an inclusion of 170 patients in each group (stent or no stent) over a period of 3 years with 1-year follow-up. The 1-year survival rate without symptomatic local recurrence was the main endpoint. Recurrence rate, survival, quality of life, and stent tolerance were secondary endpoints. During 1-year follow-up, clinical events were monitored by flexible bronchoscopies and were evaluated by an independent expert committee. <b><i>Results:</i></b> Seventy-eight patients (mean age 65 years) were randomized into 2 arms: stents (<i>n</i> = 40) or no stents (<i>n</i> = 38) after IB. Consequently, our main endpoint could not be statistically answered. Improvement of dyspnea symptoms is noticeable in each group but lasts longer in the stent group. Stents do not change the survival curve but reduce unattended bronchoscopies. In the no stent group, 19 new TB were performed with 16 stents inserted contrasting with 10 rigid bronchoscopies and 3 stents placed in the stent group. In a subgroup analysis according to the oncologic management protocol following TB (first-line treatment and other lines or palliation), the beneficial effect of stenting on obstruction recurrence was highly significant (<i>p</i> &#x3c; 0.002), but was not observed in the naïve group, free from first-line chemotherapy. <b><i>Conclusion:</i></b> Silicone stent placement maintains the benefit of TB after 1 year on dyspnea score, obstruction’s recurrence, and the need for new TB. Stenting does not affect the quality of life and is suggested for patients after failure of first-line chemotherapy. It is not suggested in patients without previous oncologic treatment.
American journal of respiratory and critical care medicine · 2004
Abstract Malignant pleural mesothelioma is an uncommon tumor largely confined to the thoracic cavity, which is resistant to conventional therapies, therefore prompting an intensive search for effective treatment alternatives. This study focuses on dendritic cell (DC) vaccination for malignant pleural mesothelioma and evaluates the in vitro efficacy of antigen-loaded DC-based vaccines for the induction of major histocompatibility complex Class I-restricted antimesothelioma cytotoxic T lymphocyte responses. The source of tumor-associated antigens for HLA-A2+ DCs from healthy donors was apoptotic HLA-A2− mesothelioma cells either lacking or expressing heat shock protein 70 according to whether tumor cells were heat shocked or not before ultraviolet-mediated apoptosis. Our results show that both apoptotic preparations were equivalent regarding the responsiveness of DCs to combined treatment with tumor necrosis factor-α and poly(inosinic-cytidylic) acid, as determined by similar increased expression of costimulatory molecules and interleukin-12 production. However, only DCs loaded with apoptotic heat shock protein 70-expressing cells were found to be potent in vitro inducers of cytotoxic T lymphocyte activity against HLA-A2+ mesothelioma cells. Such elicited cytotoxic T lymphocytes also exhibit cytotoxic activity against an HLA-A2+ melanoma cell line, suggesting recognition of shared antigens. These findings therefore carry the potential of offering an alternative, promising approach for the therapy of patients with malignant pleural mesothelioma.
Respiration; international review of thoracic diseases · 2016
<b><i>Background:</i></b> Mounier-Kuhn syndrome (MKS) is a rare disorder characterized by enlargement of the trachea and main bronchi and associated with recurrent respiratory tract infections. <b><i>Objective:</i></b> This multicenter, retrospective study was carried out to describe respiratory conditions associated with tracheobronchomegaly. <b><i>Methods:</i></b> Nine institutions involved in the ‘Groupe d'Endoscopie de Langue Française' (GELF) participated in this study. A standard form was used to record patient characteristics, treatments and follow-up from medical charts. <b><i>Results:</i></b> Seventeen patients, 53% male, aged 58 ± 18 years at diagnosis were included. Recurrent infections revealed MKS in 88% of cases. Main comorbid conditions were diffuse bronchiectasis in 88% of patients and tracheobronchomalacia in 67% of cases. The exacerbation rate was 1.5 exacerbations/patient/year. The main non-respiratory morbid condition was gastroesophageal reflux disease in 29% of cases. Interventional bronchoscopy was performed in seven patients (41%), consisting of laser (n = 2) and tracheal stenting (n = 5). Complications related to stents were observed in 80% of cases with a mean stent duration of 8 months. Four deaths, including three due to respiratory causes, occurred during follow-up. <b><i>Conclusions:</i></b> This is the largest series of MKS reported in the literature, showing that bronchiectasis and tracheobronchomalacia are the main associated morbid conditions that constitute a challenge for treatment.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Archivos de bronconeumologia · 2025 · Case Reports
Tronchetti J, Roy P, Laroumagne S, Lovato JB, et al.
ERJ open research · 2025 · Journal Article
Edme J, Fournier C, Lepage B, Zea Obando Ep Chateau C, et al.
Respiration; international review of thoracic diseases · 2025 · Journal Article
Roy P, Roy P, Amari L, Laroumagne S, et al.
Respirology (Carlton, Vic.) · 2024 · Journal Article
Daigmorte C, Usturoi D, Fournier C, Wallyn F, et al.
Respirology (Carlton, Vic.) · 2024 · Journal Article
Guibert N, Roy P, Amari L, Legodec J, et al.
Therapeutic advances in respiratory disease · 2022 · Journal Article
Delbove A, Senage T, Gazengel P, Tissot A, et al.
Respiration; international review of thoracic diseases · 2025 · Journal Article
Roy P, Roy P, Amari L, Laroumagne S, et al.
Respiration; international review of thoracic diseases · 2020 · Journal Article
Dutau H, Di Palma F, Thibout Y, Febvre M, et al.
Respiration; international review of thoracic diseases · 2016 · Journal Article
BMC geriatrics · 2026 · Journal Article
Menigoz C, Moui A, Sagan C, Carlier N, et al.
Respiratory medicine and research · 2023 · Multicenter Study
Egenod T, Guibert N, Ammar Y, Kessler R, et al.
BMC pulmonary medicine · 2022 · Journal Article
Moui A, Dirou S, Sagan C, Liberge R, et al.
Molecular cancer · 2018 · Letter
Smeele P, d'Almeida SM, Meiller C, Chéné AL, et al.
Respiration; international review of thoracic diseases · 2020 · Journal Article
Dutau H, Di Palma F, Thibout Y, Febvre M, et al.
Immune alveolitis in interstitial lung disease: an attractive cytological profile in immunocompromised patients
Abstract Background Bronchoalveolar lavage (BAL) is a major diagnostic tool in interstitial lung disease (ILD). Its use remains largely quantitative, usually focused on cell differential ratio. However, cellular morpholo
Incidence and risk factors of anastomotic complications after lung transplantation
Background:Anastomotic complications are common after lung transplantation (1.4–33% of cases) and still associated with a high morbi-mortality.Methods:The current study is a monocenter retrospective analysis of symptomat
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Schmitt P, Dalar L, Jouneau S, Toublanc B, et al.
Therapie · 2006 · Journal Article
Veyrac G, Cellerin L, Jolliet P
American journal of respiratory and critical care medicine · 2004 · Comparative Study
Ebstein F, Sapede C, Royer PJ, Marcq M, et al.